{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:52:39Z","timestamp":1793649159819,"version":"4.5.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.ejmech.2023.116015","type":"journal-article","created":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T18:12:58Z","timestamp":1701367978000},"page":"116015","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Rational design and optimization of novel 4-methyl quinazoline derivatives as PI3K\/HDAC dual inhibitors with benzamide as zinc binding moiety for the treatment of acute myeloid leukemia"],"prefix":"10.1016","volume":"264","author":[{"given":"Kehui","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songwen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deyu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhui","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouguo","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoguang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.116015_bib1","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41571-021-00509-w","article-title":"Towards precosion medicine for AML","volume":"18","author":"D\u00f6hner","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2023.116015_bib2","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/blood.2021011304","article-title":"Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal","volume":"139","author":"Estey","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2023.116015_bib3","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3324\/haematol.2022.280801","article-title":"The clinical impact of the molecular landscape of acute myeloid leukemia","volume":"108","author":"Kayser","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.ejmech.2023.116015_bib4","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","article-title":"Acute myeloid leukaemia","volume":"392","author":"Short","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2023.116015_bib5","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13045-021-01062-w","article-title":"Emerging agents and regimens for AML","volume":"14","author":"Liu","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2023.116015_bib6","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood-2015-07-604538","article-title":"Emerging therapeutic drugs for AML","volume":"127","author":"Stein","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2023.116015_bib7","doi-asserted-by":"crossref","first-page":"e922","DOI":"10.1016\/S2352-3026(21)00270-2","article-title":"Harnessing the benefits of available targeted therapies in acute myeloid leukaemia","volume":"8","author":"Kantarjian","year":"2021","journal-title":"Lancet Harmatol"},{"key":"10.1016\/j.ejmech.2023.116015_bib8","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/bjh.17746","article-title":"Updates on targeted therapies for acute myeloid leukemia","volume":"196","author":"Kayser","year":"2022","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejmech.2023.116015_bib9","doi-asserted-by":"crossref","first-page":"e350","DOI":"10.1016\/S2352-3026(22)00076-X","article-title":"Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study","volume":"9","author":"Lachowiez","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.ejmech.2023.116015_bib10","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","article-title":"The PI3K pathway in human disease","volume":"170","author":"Fruman","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2023.116015_bib11","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41568-019-0216-7","article-title":"The PI3K-AKT network at the interface of oncogenic signaling and cancer metabolism","volume":"20","author":"Hoxhaj","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2023.116015_bib12","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrc839","article-title":"The phosphatidylinositol 3-kinase AKT pathway in human cancer","volume":"2","author":"Vivanco","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2023.116015_bib13","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.semcancer.2019.07.009","article-title":"PI3K\/Akt\/mTOR inhibitors in cancer: at the bench and bedside","volume":"59","author":"Alzahrani","year":"2019","journal-title":"Cancer Biol"},{"key":"10.1016\/j.ejmech.2023.116015_bib14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12943-019-0954-x","article-title":"Targeting PI3K in cancer: mechanisms and advances in clinical trials","volume":"18","author":"Yang","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2023.116015_bib15","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s41573-021-00209-1","article-title":"PI3K inhibitors are finally coming of age","volume":"20","author":"Vanhaesebroeck","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2023.116015_bib16","doi-asserted-by":"crossref","first-page":"16033","DOI":"10.1021\/acs.jmedchem.2c01070","article-title":"Targeting the PI3K\/AKT\/mTOR signaling pathway in the treatment of human diseases: current status, trends, and solutions","volume":"65","author":"Huang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116015_bib17","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1158\/1078-0432.CCR-22-2939","article-title":"The oral PI3K\u03b4 inhibitor linperlisib for the treatment of relapsed and\/or refractory follicular lymphoma: a phase II, single-arm, open-label clinical trial","volume":"29","author":"Wang","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2023.116015_bib18","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.blre.2017.11.006","article-title":"Dueling for dual inhibition: means to enhance effectiveness of PI3K\/Akt\/mTOR inhibitors in AML","volume":"32","author":"Herschbein","year":"2018","journal-title":"Blood Rev."},{"key":"10.1016\/j.ejmech.2023.116015_bib19","first-page":"587","article-title":"The present and future of PI3K inhibitors for cancer therapy","volume":"2","author":"Castel","year":"2021","journal-title":"Nat. Can. (Ott.)"},{"key":"10.1016\/j.ejmech.2023.116015_bib20","doi-asserted-by":"crossref","first-page":"12460","DOI":"10.1021\/acs.jmedchem.0c00830","article-title":"Thirty years of HDAC inhibitors: 2020 insight and hindsight","volume":"63","author":"Ho","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116015_bib21","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd4360","article-title":"Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders","volume":"13","author":"Falkenberg","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2023.116015_bib22","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1172\/JCI69738","article-title":"New and emerging HDAC inhibitors for cancer treatment","volume":"124","author":"West","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejmech.2023.116015_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113946","article-title":"Medicinal chemistry updates of novel HDACs inhibitors (2020 to present)","volume":"227","author":"He","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116015_bib24","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13045-017-0439-6","article-title":"Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China","volume":"10","author":"Shi","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2023.116015_bib25","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13045-017-0463-6","article-title":"Emerging therapies for acute myeloid leukemia","volume":"10","author":"Saygin","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2023.116015_bib26","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1182\/blood.2020009004","article-title":"Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study","volume":"137","author":"Falchi","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2023.116015_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.582370","article-title":"Histone deacetylase inhibition in non-small cell lung cancer: hype or hope?","volume":"8","author":"Mamdani","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ejmech.2023.116015_bib28","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1002\/med.21972","article-title":"Histone deacetylase-based dual targeted inhibition in multiple myeloma","volume":"43","author":"Ferro","year":"2023","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2023.116015_bib29","doi-asserted-by":"crossref","first-page":"7482","DOI":"10.3390\/ijms24087482","article-title":"The molecular biology of prostate cancer stem cells: from the past to the future","volume":"24","author":"Zhou","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2023.116015_bib30","doi-asserted-by":"crossref","first-page":"6233","DOI":"10.1158\/0008-5472.CAN-21-1547","article-title":"A dual PI3K\/HDAC inhibitor induces immunogenic ferroptosis to potentiate cancer immune checkpoint therapy","volume":"81","author":"Fan","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2023.116015_bib31","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1021\/acs.jmedchem.7b01465","article-title":"Design, synthesis, and preclinical evaluation of fused pyrimidine-based hydroxamates for the treatment of hepatocellular carcinoma","volume":"61","author":"Chen","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116015_bib32","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1021\/acs.jmedchem.0c00193","article-title":"Design, synthesis, and biological evaluation of quinazolin-4-one-based hydroxamic acids as dual PI3K\/HDAC inhibitors","volume":"63","author":"Thakur","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116015_bib33","doi-asserted-by":"crossref","first-page":"52180","DOI":"10.1039\/C7RA08835C","article-title":"Design, synthesis and biological evaluation of 2,3-dihydroimidazo[1,2-c]quinazoline derivatives as novel phosphatidylinositol 3-kinase and histone deacetylase dual inhibitors","volume":"7","author":"Wu","year":"2017","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2023.116015_bib34","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/med.21600","article-title":"Epigenetic polypharmacology: a new frontier for epi-drug discovery","volume":"40","author":"Tomaselli","year":"2020","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2023.116015_bib35","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.3324\/haematol.2018.201343","article-title":"Antileukemia activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia","volume":"104","author":"Li","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.ejmech.2023.116015_bib36","doi-asserted-by":"crossref","first-page":"6992","DOI":"10.1021\/acs.jmedchem.9b00390","article-title":"Design, synthesis, and biological evaluation of 4-methyl quinazoline derivatives as anticancer agents simultaneously targeting phosphoinositide 3-kinases and histone deacetylases","volume":"62","author":"Zhang","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116015_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128825","article-title":"Bioevaluation of a dual PI3K\/HDAC inhibitor for the treatment of diffuse large B-cell lymphoma","volume":"71","author":"Zhang","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.116015_bib38","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1021\/acs.jmedchem.8b00189","article-title":"Kinase and histone deacetylase hybrid inhibitors for cancer therapy","volume":"62","author":"Luan","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116015_bib39","doi-asserted-by":"crossref","first-page":"7016","DOI":"10.1021\/acs.jmedchem.3c00525","article-title":"Discovery of (S)-N-(2-amino-4-fluorophenyl)-4-(1-(3-(4-((dimethylamino)methyl)phenyl)-6-oxopyridazin-1(6H)-yl)ethyl)benzamide as potent class I selective HDAC inhibitor for oral anticancer drug candidate","volume":"66","author":"Li","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116015_bib40","doi-asserted-by":"crossref","first-page":"10581","DOI":"10.1021\/acs.jmedchem.1c00683","article-title":"Rational multitargeted drug design strategy from the perspective of a medicinal chemist","volume":"64","author":"Li","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116015_bib41","doi-asserted-by":"crossref","first-page":"7698","DOI":"10.1021\/acs.jmedchem.3c00226","article-title":"The zinc-binding group effect: lessons from non-hydroxamic acid vorinostat analogs","volume":"66","author":"Geurs","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116015_bib42","doi-asserted-by":"crossref","first-page":"3769","DOI":"10.1021\/acschemneuro.9b00281","article-title":"Kinetic tuning of HDAC inhibitors affords potent inducers of progranulin expression","volume":"10","author":"Moreno-Yruela","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2023.116015_bib43","doi-asserted-by":"crossref","first-page":"35402","DOI":"10.1074\/jbc.M807045200","article-title":"Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases","volume":"283","author":"Chou","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.116015_bib44","doi-asserted-by":"crossref","first-page":"11672","DOI":"10.1021\/acs.jmedchem.3c01160","article-title":"Evolution of slow-binding inhibitors targeting histone deacetylase isoforms","volume":"66","author":"Mukherjee","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116015_bib45","doi-asserted-by":"crossref","first-page":"4802","DOI":"10.1021\/acs.jmedchem.2c01985","article-title":"Design and synthesis of triazole-containing HDAC inhibitors that induce antitumor effects and immune response","volume":"66","author":"Sun","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116015_bib46","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.chembiol.2014.12.015","article-title":"Identification of histone deacetylase inhibitors with benzoylhydrazide scaffold that selectively inhibit class I histone deacetylases","volume":"22","author":"Wang","year":"2015","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.116015_bib47","doi-asserted-by":"crossref","first-page":"8873","DOI":"10.1021\/acs.jmedchem.9b00969","article-title":"Discovery of 4-methylquinazoline based PI3K inhibitors for the potential treatment of idiopathic pulmonary fibrosis","volume":"62","author":"Lin","year":"2019","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423009820?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423009820?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:58:03Z","timestamp":1759330683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423009820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":47,"alternative-id":["S0223523423009820"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.116015","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rational design and optimization of novel 4-methyl quinazoline derivatives as PI3K\/HDAC dual inhibitors with benzamide as zinc binding moiety for the treatment of acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.116015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116015"}}